Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs

The mutations in the quinolone resistance-determining region of the gyrA and gyrB genes from 27 clinical isolates of Escherichia coli with a range of MICs of ciprofloxacin from 0.007 to 128 micrograms/ml and of nalidixic acid from 2 to > 2,000 micrograms/ml were determined by DNA sequencing. All 15 isolates with ciprofloxacin MICs of > or = 1 micrograms/ml showed a change in Ser-83 to Leu of GyrA protein, whereas in clinical isolates with a MIC of > or = 8 micrograms/ml (11 strains), a double change in Ser-83 and Asp-87 was found. All isolates with a MIC of nalidixic acid of > or = 128 micrograms/ml showed a mutation at amino acid codon Ser-83. Only 1 of the 27 clinical isolates of E. coli analyzed showed a change in Lys-447 of the B subunit of DNA gyrase. A change in Ser-83 is sufficient to generate a high level of resistance to nalidixic acid, whereas a second mutation at Asp-87 in the A subunit of DNA gyrase may play a complementary role in developing the strain's high levels of ciprofloxacin resistance.

[1]  L. Gutmann,et al.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid , 1991, Antimicrobial Agents and Chemotherapy.

[2]  N. Georgopapadakou,et al.  Routes of quinolone permeation in Escherichia coli , 1988, Antimicrobial Agents and Chemotherapy.

[3]  R. J. Reece,et al.  DNA gyrase: structure and function. , 1991, Critical reviews in biochemistry and molecular biology.

[4]  D. Hooper,et al.  Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB , 1992, Antimicrobial Agents and Chemotherapy.

[5]  J. Wang,et al.  Mapping the active site tyrosine of Escherichia coli DNA gyrase. , 1987, The Journal of biological chemistry.

[6]  B. Gatto,et al.  On the mechanism of action of quinolone drugs. , 1993, Trends in microbiology.

[7]  S. Nakamura,et al.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli , 1990, Antimicrobial Agents and Chemotherapy.

[8]  L. Fisher,et al.  4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction , 1991, Antimicrobial Agents and Chemotherapy.

[9]  A. Wyke,et al.  Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones , 1989, Antimicrobial Agents and Chemotherapy.

[10]  T J O'Donnell,et al.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. , 1989, Biochemistry.

[11]  A. Maxwell,et al.  A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex , 1993, Antimicrobial Agents and Chemotherapy.

[12]  S. Nakamura,et al.  Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli , 1990, Antimicrobial Agents and Chemotherapy.

[13]  A. Maxwell,et al.  Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: enzymatic analysis of the mutant proteins , 1991, Antimicrobial Agents and Chemotherapy.

[14]  L. Gutmann,et al.  Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid , 1993, Antimicrobial Agents and Chemotherapy.

[15]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[16]  P. Heisig,et al.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli , 1993, Antimicrobial Agents and Chemotherapy.

[17]  S. Mitsuhashi,et al.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.

[18]  A. Maxwell.  The molecular basis of quinolone action. , 1992, The Journal of antimicrobial chemotherapy.

[19]  D. Hooper,et al.  Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation , 1989, Antimicrobial Agents and Chemotherapy.

[20]  W. Kohlbrenner,et al.  Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes. , 1989, The Journal of biological chemistry.

[21]  D. Hooper,et al.  Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction , 1989, Antimicrobial Agents and Chemotherapy.

[22]  A. Pernet,et al.  Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Hooper,et al.  Endogenous active efflux of norfloxacin in susceptible Escherichia coli , 1988, Antimicrobial Agents and Chemotherapy.

[24]  W. M. Huang,et al.  Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations , 1993, Antimicrobial Agents and Chemotherapy.

[25]  D. Hooper,et al.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro , 1985, Antimicrobial Agents and Chemotherapy.